Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide.
The authors report the clinical, echocardiographic, and pathologic findings in two patients treated with more than 5 mg of pergolide daily who developed symptomatic severe heart failure due to restrictive valvular disease. They also describe the echocardiographic data of another eight patients taking similar doses of pergolide presenting no clinical signs of heart failure. The findings suggest a possible role of high doses of pergolide in inducing restrictive valvular disease.
D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001022:Aortic Valve Insufficiency / Q000139:chemically induced / Q000000981:diagnostic imaging; D004452:Echocardiography; D017809:Fatal Outcome; D005260:Female; D006349:Heart Valve Diseases / Q000139:chemically induced* / Q000150:complications / Q000000981:diagnostic imaging; D006801:Humans; D008297:Male; D008875:Middle Aged; D008944:Mitral Valve Insufficiency / Q000139:chemically induced / Q000000981:diagnostic imaging; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy*; D010479:Pergolide / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D014262:Tricuspid Valve Insufficiency / Q000139:chemically induced / Q000000981:diagnostic imaging
D000978:Antiparkinson Agents; D010479:Pergolide